You are here: Home: Audio Program Guide: CCU Surgeons 1 | 2007 - Audio: CCU Surgeons 1 | 2007
Go to interview with Norman Wolmark, MD Go to interview with Lee M Ellis, MD Go to interview with Howard S Hochster, MD
To listen to individual tracks, click the on the track you wish to listen to. To download tracks, right-click on the one you wish to download.

 

Norman Wolmark, MD Professor and Chairman Department of Human Oncology Allegheny General Hospital Professor, Drexel University College of Medicine Chairman, National Surgical Adjuvant Breast and Bowel Project Pittsburgh, Pennsylvania
	Click here to download the entire interview
Track 1	Recent evolution of treatment for colon cancer
Track 2	Side effects and toxicity of adjuvant oxaliplatin-containing regimens
Track 3	Adjuvant therapy for patients with Stage II colon cancer
Track 4	Adequacy of lymph node sampling in colon cancer
Track 5	Development of a multigene assay for estimating prognoses in colon cancer
Track 6	NSABP-C-08 and AVANT trials: Adjuvant FOLFOX/CAPOX with or without bevacizumab
Track 7	Proposed NSABP-C-11 adjuvant trial: Chemotherapy/bevacizumab with or without an EGFR monoclonal antibody
Track 8	Side effects and toxicity of adjuvant oxaliplatin-containing chemotherapy with bevacizumab
Track 9	Patient acceptance of EGFR inhibitor-associated rash during adjuvant therapy
Track 10	NSABP-C-09: CAPOX with or without hepatic arterial infusion of FUDR for patients with resected or ablated hepatic metastases
Track 11	Resectability of hepatic and extrahepatic metastases
Track 12	NSABP-C-10: FOLFOX and bevacizumab for metastatic and synchronous asymptomatic primary colon cancer
Track 13	NSABP-R-04: Preoperative capecitabine or 5-FU, with or without oxaliplatin with radiation therapy for rectal cancer

Lee M Ellis, MD Professor of Surgery and Cancer Biology The University of Texas MD Anderson Cancer Center Houston, Texas
	Click here to download the entire interview
Track 1	Role of the surgeon in identifying patients to consider adjuvant therapy
Track 2	Tolerability of oxaliplatin-containing adjuvant chemotherapy
Track 3	Surgical issues in lymph node sampling
Track 4	Identifying patients with Stage II disease who may benefit from adjuvant therapy
Track 5	Laparoscopic versus open colectomy
Track 6	Molecular markers to predict benefit from adjuvant systemic therapy
Track 7	Ongoing adjuvant studies of FOLFOX with or without bevacizumab
Track 8	BRiTE registry and bevacizumab-associated bowel perforations
Track 9	Wound healing and bevacizumab
Track 10	Potential mechanisms of action of bevacizumab
Track 11	Clinical management of synchronous primary and metastatic colon cancer
Track 12	Bevacizumab-associated side effects and complications
Track 13	Determination of resectability of hepatic metastases
Track 14	Use of systemic therapy to convert unresectable metastases to resectable disease
Track 15	Use of intra-arterial hepatic infusion of chemotherapy
Track 16	Preoperative chemoradiation therapy for rectal cancer
Track 17	Postoperative adjuvant chemotherapy for rectal cancer
Track 18	Total mesorectal excision in rectal cancer
Track 19	Dose-response relationship with bevacizumab
Track 20	Biologic agents and wound healing
Track 21	Combination versus sequential administration of chemotherapy and biologic therapy

Howard S Hochster, MD Professor of Medicine and Clinical Pharmacology NYU Cancer Institute New York, New York
	Click here to download the entire interview
Track 1	Evolution of adjuvant therapy for colorectal cancer
Track 2	Tolerability and side effects of oxaliplatin
Track 3	Adjuvant oxaliplatin-containing regimens: FOLFOX and FLOX
Track 4	Benefit of adjuvant therapy for patients with Stage II disease
Track 5	ECOG-E5202: Treatment of Stage II disease based on molecular markers
Track 6	Incorporation of the number of lymph nodes sampled into treatment decision-making
Track 7	Use of capecitabine with or without oxaliplatin for patients with Stage II colon cancer
Track 8	Oxaliplatin-containing adjuvant chemotherapy for the elderly
Track 9	Oxaliplatin-associated neurotoxicity
Track 10	Background to the current clinical trials of adjuvant chemotherapy with or without biologic therapy
Track 11	Potential mechanisms of action of bevacizumab
Track 12	Potential adverse events associated with bevacizumab
Track 13	Bevacizumab and bowel perforations
Track 14	Converting unresectable hepatic metastases to resectable disease
Track 15	Use of intrahepatic chemotherapy in clinical practice
Track 16	Anti-EGFR monoclonal antibodies cetuximab and panitumumab in colon cancer
Track 17	Clinical trials combining anti-EGFR antibodies with bevacizumab
Track 18	Negative outcomes of combining bevacizumab and panitumumab on the PACCE trial
Track 19	Clinical decision-making for patients with synchronous primary and metastatic colon cancer
Track 20	Neoadjuvant chemoradiation therapy for rectal cancer